GCM
VRTX icon

Genus Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Genus Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-445
Closed -$209K – 223
2024
Q2 		$209K Buy
+445
New +$193K 0.03% 181
2024
Q1 		– Sell
-555
Closed -$226K – 381
2023
Q4 		$226K Buy
+555
New +$205K 0.03% 180

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Genus Capital Management's VRTX Position: Q3 2025 in Review

Genus Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 4,370 shares — an estimated $1.95M sold.

Genus Capital Management first reported a position in VRTX in Q2 2023 and held it in 3 quarters. The position peaked at $2.32M in Q1 2025. 1,521 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Genus Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Genus Capital Management sold 4,370 Vertex Pharmaceuticals shares in Q3 2025, an estimated $1.95M.
  • Genus Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Genus Capital Management's Vertex Pharmaceuticals position peaked at $2.32M in Q1 2025.
  • 1,521 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Genus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.